Ocular Therapeutix Axpaxli Advances In Phase 3 For Wet AMD, Analyst Forecasts Huge Upside
1. Needham initiated coverage on OCUL, rating it a Buy with a $15 target. 2. Axpaxli is under evaluation in two phase 3 trials for wet AMD. 3. Positive trial results could offer extended treatment duration for wet AMD. 4. The company expects to fund operations into 2028 with existing cash reserves. 5. Needham estimates peak sales of Axpaxli could reach $1.5 billion.